VYNE Therapeutics (NASDAQ:VYNE) Posts Quarterly Earnings Results, Misses Estimates By $3.33 EPS

VYNE Therapeutics (NASDAQ:VYNE) posted its quarterly earnings results on Thursday. The company reported ($3.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($3.33), FiscalAI reports. The company had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.20 million. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.

VYNE Therapeutics Price Performance

Shares of NASDAQ VYNE traded down $0.23 during midday trading on Friday, reaching $28.32. 93,278 shares of the stock were exchanged, compared to its average volume of 44,151. VYNE Therapeutics has a 12 month low of $14.03 and a 12 month high of $79.75. The company has a market capitalization of $18.98 million, a price-to-earnings ratio of -74.54 and a beta of 2.00. The business has a 50-day simple moving average of $32.53 and a two-hundred day simple moving average of $31.46.

VYNE Therapeutics Dividend Announcement

The company also recently declared a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were given a dividend of $19.00 per share.

Institutional Trading of VYNE Therapeutics

Several hedge funds have recently added to or reduced their stakes in VYNE. KVP Capital Advisors LP acquired a new position in VYNE Therapeutics in the fourth quarter valued at about $290,000. XTX Topco Ltd bought a new position in shares of VYNE Therapeutics during the 4th quarter valued at about $46,000. ADAR1 Capital Management LLC bought a new position in shares of VYNE Therapeutics during the 4th quarter valued at about $147,000. Anson Funds Management LP acquired a new position in shares of VYNE Therapeutics in the 4th quarter valued at approximately $739,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of VYNE Therapeutics in the 4th quarter valued at approximately $580,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of VYNE Therapeutics in a research note on Monday, May 4th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, VYNE Therapeutics presently has a consensus rating of “Sell”.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.